1. Calcein represses human papillomavirus 16 E1-E2 mediated DNA replication via blocking their binding to the viral origin of replication
- Author
-
Iain M. Morgan, Stacie L. Richardson, Matthew C. T. Hartman, Nathan W. Smith, Xu Wang, and Dipon Das
- Subjects
DNA Replication ,0301 basic medicine ,Human papillomavirus 16 ,biology ,Papillomavirus Infections ,DNA replication ,Replication Origin ,Eukaryotic DNA replication ,Oncogene Proteins, Viral ,Fluoresceins ,Origin of replication ,Antiviral Agents ,Virology ,DNA-Binding Proteins ,DNA replication factor CDT1 ,03 medical and health sciences ,030104 developmental biology ,Replication factor C ,Control of chromosome duplication ,Viral replication complex ,biology.protein ,Humans ,Origin recognition complex ,Protein Binding - Abstract
Human papillomaviruses are causative agents in several human diseases ranging from genital warts to ano-genital and oropharyngeal cancers. Currently only symptoms of HPV induced disease are treated; there are no antivirals available that directly target the viral life cycle. Previously, we determined that the cellular protein TopBP1 interacts with the HPV16 replication/transcription factor E2. This E2-TopBP1 interaction is essential for optimal E1-E2 DNA replication and for the viral life cycle. The drug calcein disrupts the interaction of TopBP1 with itself and other host proteins to promote cell death. Here we demonstrate that calcein blocks HPV16 E1-E2 DNA replication via blocking the viral replication complex forming at the origin of replication. This occurs at non-toxic levels of calcein and demonstrates specificity as it does not block the ability of E2 to regulate transcription. We propose that calcein or derivatives could be developed as an anti-HPV therapeutic.
- Published
- 2017